Erythrocyte Aggregation via Dextran and Antibody for Cell Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for separating erythrocytes from blood samples, such as hypotonic lysis, density gradient separation, and centrifugal sedimentation using hetastarch, are inefficient and result in poor recovery of rare cell types like hematopoietic stem cells and lymphocytes, leading to contamination and reduced engraftment potential in therapies.
Innovation Solution
A composition comprising dextran, anti-glycophorin A antibodies, heparin, and a calcium chelator that specifically aggregates erythrocytes via surface antigen recognition, facilitating their enhanced sedimentation at 1×g, allowing for the recovery of non-erythroid cells like leukocytes and stem cells from the supernatant.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If density gradient separation is used to remove erythrocytes, then erythrocyte removal is achieved, but rare cell types like stem cells and lymphocytes are lost due to poor separation precision
Solution Approach 1:
The patent introduces dextran as an intermediary substance that mediates between erythrocytes and the separation process. Dextran specifically binds to erythrocyte surface antigens (glycophorin A and B), forming erythrocyte-dextran complexes that sediment at a different rate than rare cell types, thereby achieving precise separation without losing stem cells or lymphocytes
Solution Approach 2:
The patent changes the physical-chemical parameters of erythrocytes by introducing dextran, which alters their sedimentation characteristics. The dextran-erythrocyte complexes have different density and sedimentation rates compared to native erythrocytes, enabling selective removal while preserving rare cell types through controlled parameter modification
2Quantity of substance
If hypotonic lysis is used to remove erythrocytes, then erythrocyte removal is achieved, but the method is inefficient for large volumes of blood
Solution Approach 1:
The patent replaces the chemical mechanism of hypotonic lysis with a physical sedimentation mechanism using dextran. Instead of causing erythrocytes to burst through osmotic pressure changes, the dextran-induced aggregation method allows intact erythrocytes to be removed through controlled sedimentation, which is more efficient for large volume processing
3Quantity of substance
If heta starch is used to stimulate erythrocyte aggregation, then erythrocyte removal is achieved, but recovery of important cell types is highly variable and often poor
Solution Approach 1:
The patent modifies the chemical composition parameters by replacing heta starch with dextran, which has different molecular weight and binding characteristics. Dextran provides more consistent and controllable aggregation of erythrocytes, leading to predictable and reproducible separation outcomes across different sample types and conditions
Solution Approach 2:
Dextran serves as a more effective intermediary substance compared to heta starch, with specific affinity for erythrocyte surface antigens. This targeted binding creates uniform erythrocyte-dextran complexes that sediment consistently, improving the reliability and consistency of cell type recovery across various samples
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables high-yield recovery of rare cell types, reducing contamination and improving the success of transplant and immune therapies by efficiently separating erythrocytes from other blood components.
Implementation Method 1
compositions of the invention can fractionate blood samples by specifically aggregating erythrocytic cells via surface antigen recognition
Implementation Method 2
stimulating the enhanced sedimentation of erythrocytes at 1×g
Data Source
AI summary
The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover rare cell types in high yield.